Citations (303)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (38)
Güliz Şenormancı, Nimet Korkmaz, Ömer Şenormancı, Selen Uğur, Mine Topsaç & Okan Gültekin. (2021) Effects of Exercise on Resilience, Insight and Functionality in Patients with Chronic Schizophrenia in a Psychiatric Nursing Home Setting: A Randomized Controlled Trial. Issues in Mental Health Nursing 42:7, pages 690-698.
Read now
Read now
Aaron Benjamin Philip & Luiz Dratcu. (2021) Psychotic disorders and electrocardiogram abnormalities in the acute psychiatric setting: more than the metabolic syndrome alone. International Journal of Psychiatry in Clinical Practice 25:1, pages 103-105.
Read now
Read now
Nađa P. Marić, Sanja Andrić Petrović, Stefan Jerotić, Ivan Ristić, Bojana Savić, Mirjana Zebić, Vuk Vuković, Dubravka Britvić, Olivera Golubović, Marko Jakšić, Katarina Jevđić, Zorica Kolašinac, Nikola Lalović, Jasminka Mirković Ilić, Slavica Nikolić, Čedica Paunović, Zorana Pavlović, Slobodanka Pejović Nikolić, Vukašin Perović, Jelena Popović, Vesna Ranđić Avakumović, Snežana Stojanović, Milan Tatarević, Ivana Živković, Tatjana Voskresenski & Nikolina Jovanović. (2020) Maintenance phase treatment of psychotic disorders in outpatients from Serbia – focus on long-term benzodiazepine use. International Journal of Psychiatry in Clinical Practice 24:3, pages 315-321.
Read now
Read now
Francesco Pietrini, Umberto Albert, Andrea Ballerini, Paola Calò, Giuseppe Maina, Federica Pinna, Marco Vaggi, Ileana Boggian, Maria Fontana, Cesare Moro & Bernardo Carpiniello. (2019) The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1045-1060.
Read now
Read now
Timothy Peters-Strickland, Ross A Baker, Pedro Such, Peter Zhang & Jessica J Madera. (2019) The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies. Neuropsychiatric Disease and Treatment 15, pages 1659-1669.
Read now
Read now
Tianmei Si, Jianmin Zhuo, Yu Feng, Huafei Lu, Di Hong & Lili Zhang. (2019) Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1685-1694.
Read now
Read now
Christy L. M. Hui, Bertha S. T. Lam, Edwin H. M. Lee, Sherry K. W. Chan, Wing C. Chang, Y. N. Suen & Eric Y. H. Chen. (2019) A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia. International Review of Psychiatry 31:5-6, pages 441-459.
Read now
Read now
Hubertus Himmerich, Jessica Bentley, Nicole Lichtblau, Clare Brennan & Katie Au. (2019) Facets of shared decision-making on drug treatment for adults with an eating disorder. International Review of Psychiatry 31:4, pages 332-346.
Read now
Read now
Timothy G. Dinan & John F. Cryan. (2018) Schizophrenia and the microbiome: Time to focus on the impact of antipsychotic treatment on the gut microbiota. The World Journal of Biological Psychiatry 19:8, pages 568-570.
Read now
Read now
Michael Davidson. (2018) The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues in Clinical Neuroscience 20:3, pages 215-221.
Read now
Read now
Nenad Vasic, Felix Segmiller, Felix Rees, Markus Jäger, Thomas Becker, Norbert Ormanns, Stefanie Otte, Judith Streb & Manuela Dudeck. (2018) Psychopharmacologic treatment of in-patients with schizophrenia: comparing forensic and general psychiatry. The Journal of Forensic Psychiatry & Psychology 29:1, pages 1-15.
Read now
Read now
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll & André F Carvalho. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management 13, pages 757-777.
Read now
Read now
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni & Paola Rocca. (2017) Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2767-2779.
Read now
Read now
Robin Emsley, Ludger Hargarter, Paul Bergmans, Boran Uglešić, Abdullah Cem Sengül, Antonino Petralia, Angelina Khannanova, Pierre Cherubin & Andreas Schreiner. (2017) Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2261-2269.
Read now
Read now
Phyllis M Salzman, Arash Raoufinia, Susan Legacy, Pedro Such & Anna Eramo. (2017) Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatric Disease and Treatment 13, pages 1125-1129.
Read now
Read now
Kathleen Beusterien, Elcie Chan, Pedro Such, Anne de Jong Laird, Stephan Heres, Kaitlan Amos, Jean-Yves Loze, Anna-Greta Nylander, Paul Robinson & John F. P. Bridges. (2017) Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophrenia. Current Medical Research and Opinion 33:12, pages 2129-2136.
Read now
Read now
Mikkel Højlund, Anja Friis Elliott, Nikolaj Juul Madsen, Anne Grethe Viuff, Povl Munk-Jørgensen & Peter Hjorth. (2017) Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia. Nordic Journal of Psychiatry 71:8, pages 598-604.
Read now
Read now
Svetlana A. Ivanova, Diana Z. Osmanova, Maxim B. Freidin, Olga Yu Fedorenko, Anastasia S. Boiko, Ivan V. Pozhidaev, Arkadiy V. Semke, Nikolay A. Bokhan, Alexey A. Agarkov, Bob Wilffert & Anton J.M. Loonen. (2017) Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. The World Journal of Biological Psychiatry 18:3, pages 239-246.
Read now
Read now
Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthøj, Wagner F. Gattaz, Florence Thibaut & Hans-Jürgen Möller. (2017) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. International Journal of Psychiatry in Clinical Practice 21:2, pages 82-90.
Read now
Read now
Pierre Baumann, Marie Spies, Hans-Jürgen Möller, Siegfried Kasper, Istvan Bitter & Gerd Laux. (2017) A proposal for a psychopharmacology–pharmacotherapy catalogue of learning objectives and a curriculum in Europe. The World Journal of Biological Psychiatry 18:1, pages 29-38.
Read now
Read now
Andrea de Bartolomeis, Andrea Fagiolini, Marco Vaggi & Claudio Vampini. (2016) Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatric Disease and Treatment 12, pages 99-108.
Read now
Read now
Cristiana Montemagni, Tiziana Frieri & Paola Rocca. (2016) Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatric Disease and Treatment 12, pages 917-929.
Read now
Read now
Andrea Murru, Diego Hidalgo, Miquel Bernardo, Julio Bobes, Jerónimo Saiz-Ruiz, Cecilio Álamo & Eduard Vieta. (2016) Antipsychotic switching in schizoaffective disorder: A systematic review. The World Journal of Biological Psychiatry 17:7, pages 495-513.
Read now
Read now
Marc De Hert, Johan Detraux & Brendon Stubbs. (2016) Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opinion on Drug Safety 15:6, pages 809-823.
Read now
Read now
Irma H. Mahone, Chris Fasching Maphis & Diane E. Snow. (2016) Effective Strategies for Nurses Empowering Clients With Schizophrenia: Medication Use as a Tool in Recovery. Issues in Mental Health Nursing 37:5, pages 372-379.
Read now
Read now
Markus Dold, Magdolna Tardy, Myrto T. Samara, Chunbo Li, Siegfried Kasper & Stefan Leucht. (2016) Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. The World Journal of Biological Psychiatry 17:3, pages 210-220.
Read now
Read now
Ludovic Samalin, Ricardo Garay, Ahcène Ameg & Pierre-Michel Llorca. (2016) Olanzapine pamoate for the treatment of schizophrenia – a safety evaluation. Expert Opinion on Drug Safety 15:3, pages 403-411.
Read now
Read now
Marc De Hert, Anna Eramo, Wally Landsberg, Dusan Kostic, Lan-Feng Tsai & Ross A Baker. (2015) Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis. Neuropsychiatric Disease and Treatment 11, pages 1299-1306.
Read now
Read now
Ernie Anand, Lovisa Berggren, Claudia Deix, Ágoston Tóth & David P McDonnell. (2015) A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. Neuropsychiatric Disease and Treatment 11, pages 1349-1357.
Read now
Read now
Rene S Kahn & Amalia Giannopoulou. (2015) The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Review of Neurotherapeutics 15:9, pages 969-981.
Read now
Read now
Mathias Zink & Christoph U Correll. (2015) Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Review of Clinical Pharmacology 8:3, pages 335-352.
Read now
Read now
Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthøj, Wagner F. Gattaz, Florence Thibaut & Hans-Jürgen Möller. (2015) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry 16:3, pages 142-170.
Read now
Read now
Arash Raoufinia, Ross A. Baker, Anna Eramo, Anna-Greta Nylander, Wally Landsberg, Dusan Kostic & Frank Larsen. (2015) Initiation of aripiprazole once-monthly in patients with schizophrenia. Current Medical Research and Opinion 31:3, pages 583-592.
Read now
Read now
John M. Kane, Cathy Zhao, Brian R. Johnson, Ross A. Baker, Anna Eramo, Robert D. McQuade, Anna R. Duca, Raymond Sanchez & Timothy Peters-Strickland. (2015) Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics 18:2, pages 145-154.
Read now
Read now
Stephanie M Perez & Daniel J Lodge. (2014) New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. Drug Design, Development and Therapy 8, pages 887-896.
Read now
Read now
Eva Ceskova. (2014) The need to improve current psychopharmacotherapy before developing new drugs. Expert Opinion on Pharmacotherapy 15:14, pages 1969-1973.
Read now
Read now
Andreas Schreiner, Anders Svensson, Robert Wapenaar, Pierre Cherubin, Patricia Princet, Larisa Serazetdinova & Mathias Zink. (2014) Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). The World Journal of Biological Psychiatry 15:7, pages 534-545.
Read now
Read now
Leslie Citrome, Siddhesh A. Kamat, Christophe Sapin, Ross A. Baker, Anna Eramo, Jesse Ortendahl, Benjamin Gutierrez, Karina Hansen & Tanya G. K. Bentley. (2014) Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics 17:8, pages 567-576.
Read now
Read now
Articles from other publishers (265)
Bernhard T. Baune. (2023) Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Current Medical Research and Opinion, pages 1-23.
Crossref
Crossref
Michael Davidson & William T CarpenterJrJr. (2023) Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence. Schizophrenia Bulletin.
Crossref
Crossref
Tiannan Shao, Jing Huang, Yuxin Zhao, Weiyan Wang, Xiaohan Tian, Gangrui Hei, Dongyu Kang, Yong Gao, Fangkun Liu, Jingping Zhao, Bing Liu, Ti-Fei Yuan & Renrong Wu. (2023) Metformin improves cognitive impairment in patients with schizophrenia: associated with enhanced functional connectivity of dorsolateral prefrontal cortex. Translational Psychiatry 13:1.
Crossref
Crossref
ZhenYu Zhu, Ting Cao, Hui Chen, BiKui Zhang, ChenQuan Lin & HuaLin Cai. (2023) Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling. Food and Chemical Toxicology 176, pages 113757.
Crossref
Crossref
Agnieszka Matuszewska, Krzysztof Kowalski, Paulina Jawień, Tomasz Tomkalski, Dagmara Gaweł-Dąbrowska, Anna Merwid-Ląd, Ewa Szeląg, Karolina Błaszczak, Benita Wiatrak, Maciej Danielewski, Janusz Piasny & Adam Szeląg. (2023) The Hypothalamic-Pituitary-Gonadal Axis in Men with Schizophrenia. International Journal of Molecular Sciences 24:7, pages 6492.
Crossref
Crossref
Christoph U Correll, Evan Stein, Christine Graham, Lauren DiPetrillo, Sarah Akerman, Arielle D Stanford, Ying Jiang, Sergey Yagoda, David McDonnell & Craig Hopkinson. (2023) Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study. Schizophrenia Bulletin 49:2, pages 454-463.
Crossref
Crossref
Leo Malandain & Florence Thibaut. (2023) Is there Any Relevance for the Use of Cyamemazine in the Treatment of Schizophrenia?. Indian Journal of Private Psychiatry 17:1, pages 14-19.
Crossref
Crossref
Paola Testini & Stewart A. Factor. (2023) Treatment of tardive dystonia: A review. Dystonia 2.
Crossref
Crossref
Nicolaas Martens, Eline De Haeck, Evelyn Van De Vondel, Marianne Destoop, Kirsten Catthoor, Geert Dom & Kris Van Den Broeck. (2023) Physical Healthcare for People with a Severe Mental Illness in Belgium by Long-Term Community Mental Health Outreach Teams: A Qualitative Descriptive Study on Physicians’, Community Mental Health Workers’ and Patients’ Perspectives. International Journal of Environmental Research and Public Health 20:1, pages 811.
Crossref
Crossref
Hiroyuki Uchida, Euitae Kim, L. Fredrik Jarskog, W. Wolfgang Fleischhacker, Gary Remington & Jeffrey A. Lieberman. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
58
.
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2022) The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up. Biomedicines 11:1, pages 42.
Crossref
Crossref
Andrea Fagiolini, Miriam Olivola, Lisa Lavatelli, Antonello Bellomo, Caterina Lobaccaro, Nathalie Falsetto, Marco Micillo & Alessandro Cuomo. (2022) Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice. Annals of General Psychiatry 21:1.
Crossref
Crossref
Ilaria Riboldi, Daniele Cavaleri, Chiara A Capogrosso, Cristina Crocamo, Francesco Bartoli & Giuseppe Carrà. (2022) Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia. Psychology Research and Behavior Management Volume 15, pages 3915-3929.
Crossref
Crossref
Shangda Li, Renchuan Liu, Bin Sun, Ning Wei, Zhe Shen, Yi Xu & Manli Huang. (2022) Effect of Virtual Reality on Cognitive Impairment and Clinical Symptoms among Patients with Schizophrenia in the Remission Stage: A Randomized Controlled Trial. Brain Sciences 12:11, pages 1572.
Crossref
Crossref
Yumi Aoki, Yukari Yaju, Tomohiro Utsumi, Leigh Sanyaolu, Marianne Storm, Yoshikazu Takaesu, Koichiro Watanabe, Norio Watanabe, Edward Duncan & Adrian GK Edwards. (2022) Shared decision-making interventions for people with mental health conditions. Cochrane Database of Systematic Reviews 2022:11.
Crossref
Crossref
Hiroyuki Kamei. (2022) Polypharmacy Management of Antipsychotics in Patients with Schizophrenia. Medicina 58:11, pages 1584.
Crossref
Crossref
Cecilio Álamo. (2022) Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. Advances in Therapy 39:11, pages 4875-4891.
Crossref
Crossref
Jonathan M. Meyer, Adam Simmons, Ying Jiang, Christine Graham, Sergey Yagoda & David McDonnell. (2022) Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. CNS Spectrums, pages 1-4.
Crossref
Crossref
Sanghoon Oh, Sun-ju Byeon & Soo Jie Chung. (2022) Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Journal of Psychopharmacology 36:9, pages 1041-1050.
Crossref
Crossref
Simon Digé & Julia Bodin. (2022) Symptômes psychotiques et psychostimulants. Annales Médico-psychologiques, revue psychiatrique.
Crossref
Crossref
Laura Orsolini, Simone Pompili & Umberto Volpe. (2022) Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects. Journal of Clinical Medicine 11:17, pages 5040.
Crossref
Crossref
Mohammed S. Alasmari, Fawaz Alasmari, Abdullah F. Alasmari, Aws Alshamsan, Sary Alsanea, Muhammad F. Rasool & Faleh Alqahtani. (2022) Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations. Pharmaceutics 14:9, pages 1795.
Crossref
Crossref
Yoshikazu Takaesu, Yumi Aoki, Yui Tomo, Takashi Tsuboi, Miho Ishii, Yayoi Imamura, Hisateru Tachimori & Koichiro Watanabe. (2022) Implementation of a shared decision-making training program for clinicians based on the major depressive disorder guidelines in Japan: A multi-center cluster randomized trial. Frontiers in Psychiatry 13.
Crossref
Crossref
Joshua Gerving, Heather Walser & Anne C. Kelly. (2022) Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy. Mental Health Clinician 12:4, pages 263-266.
Crossref
Crossref
Hannah A. Blair. (2022) Paliperidone palmitate intramuscular 6-monthly formulation in schizophrenia: a profile of its use. Drugs & Therapy Perspectives 38:8, pages 335-342.
Crossref
Crossref
Lamia Jouini, Uta Ouali, Sami Ouanes, Mouna Ben Djebara, Fethi Nacef & Riadh Gouider. (2022) Akathisia Among Patients Undergoing Antipsychotic Therapy: Prevalence, Associated Factors, and Psychiatric Impact. Clinical Neuropharmacology 45:4, pages 89-94.
Crossref
Crossref
Nana Liang, Xinrong Li, Xianju Guo, Sha Liu, Yao Liu, Wentao Zhao, Yujiao Wen, Yue Li, Jing Li, Fangya Li, Haiyan Wu, Jianhong Li, Qiqi Li, Jianxia Guo & Yong Xu. (2022) Visual P300 as a neurophysiological correlate of symptomatic improvement by a virtual reality-based computer AT system in patients with auditory verbal hallucinations: A Pilot study. Journal of Psychiatric Research 151, pages 261-271.
Crossref
Crossref
Ana-Aliana Miron, Andreea Teodorescu, Petru Ifteni, Claudia Alexandrina Irimie, Lorena Dima & Paula-Simina Petric. (2022) Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study. Psychiatric Quarterly 93:2, pages 627-635.
Crossref
Crossref
Peter Falkai & Andrea Schmitt. (2022) Failed regeneration and inflammation in schizophrenia: two sides of the same coin?. Journal of Neural Transmission 129:5-6, pages 611-615.
Crossref
Crossref
Peter Falkai, Andrea Schmitt, Christian P. Rosenbeiger, Isabel Maurus, Lisa Hattenkofer, Alkomiet Hasan, Berend Malchow, Pascale Heim-Ohmayer, Martin Halle & Melanie Heitkamp. (2021) Aerobic exercise in severe mental illness: requirements from the perspective of sports medicine. European Archives of Psychiatry and Clinical Neuroscience 272:4, pages 643-677.
Crossref
Crossref
L. Malandain, M. Leygues & F. Thibaut. (2021) Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study. European Archives of Psychiatry and Clinical Neuroscience 272:4, pages 583-590.
Crossref
Crossref
Sung Woo Joo, Harin Kim, Young Tak Jo, Soojin Ahn, Young Jae Choi, Woohyeok Choi, Soyeon Park & Jungsun Lee. (2022) Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first‐episode schizophrenia: A nationwide, health insurance data–based study. Psychiatry and Clinical Neurosciences 76:5, pages 195-200.
Crossref
Crossref
Luis Gutiérrez‐Rojas, Sergio Sánchez-Alonso, Marta García Dorado & Paola M. López Rengel. (2022) Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS Drugs 36:5, pages 517-527.
Crossref
Crossref
Nadja P. Maric, Sanja Andric Petrovic, Manuela Russo, Stefan Jerotic, Ivan Ristic, Bojana Savić, Tamara Pemovska, Milos Milutinovic, Emina Ribic, Silvana Markovska-Simoska, Alma Dzubur Kulenovic & Nikolina Jovanovic. (2022) Maintenance Therapy of Psychosis Spectrum Disorders in a Real-World Setting: Antipsychotics Prescription Patterns and Long-Term Benzodiazepine Use. Frontiers in Psychiatry 13.
Crossref
Crossref
Flavien Thuaire, Fabien Rondepierre, Guillaume T. Vallet, Isabelle Jalenques & Marie Izaute. (2020) Executive deficits in schizophrenia: mediation by processing speed and its relationships with aging. Psychological Medicine 52:6, pages 1126-1134.
Crossref
Crossref
Petros Drosos, Erik Johnsen, Christoffer Andreas Bartz-Johannessen, Tor Ketil Larsen, Solveig Klæbo Reitan, Maria Rettenbacher & Rune Andreas Kroken. (2022) Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness. World Journal of Psychiatry 12:3, pages 521-532.
Crossref
Crossref
Dan Siskind, Stacy Orr, Surabhi Sinha, Ou Yu, Bhavna Brijball, Nicola Warren, James H MacCabe, Sophie E Smart & Steve Kisely. (2021) Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. The British Journal of Psychiatry 220:3, pages 115-120.
Crossref
Crossref
Ofer Agid, Gary Remington, Carmen Fung, Natalie M. Nightingale, Marc Duclos & Gregory J. Anger. (2021) Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study. The Canadian Journal of Psychiatry 67:3, pages 226-234.
Crossref
Crossref
Christoph U. Correll, Amber Martin, Charmi Patel, Carmela Benson, Rebecca Goulding, Jennifer Kern-Sliwa, Kruti Joshi, Emma Schiller & Edward Kim. (2022) Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia 8:1.
Crossref
Crossref
Piotr Podwalski, Ernest Tyburski, Krzysztof Szczygieł, Krzysztof Rudkowski, Katarzyna Waszczuk, Wojciech Andrusewicz, Jolanta Kucharska-Mazur, Anna Michalczyk, Monika Mak, Katarzyna Cyranka, Błażej Misiak, Leszek Sagan & Jerzy Samochowiec. (2022) Psychopathology and Integrity of the Superior Longitudinal Fasciculus in Deficit and Nondeficit Schizophrenia. Brain Sciences 12:2, pages 267.
Crossref
Crossref
Martijn J. Kikkert, Wim Veling, Lieuwe de Haan, Marieke J. H. Begemann, Mariken de Koning & Iris E. Sommer. (2021) Medication strategies in first episode psychosis patients: A survey among psychiatrists. Early Intervention in Psychiatry 16:2, pages 139-146.
Crossref
Crossref
Yusuke Okada & Manabu Akazawa. (2021) Effects of medical service fee revision on reducing irrational psychotropic polypharmacy in Japan: an interrupted time-series analysis. Social Psychiatry and Psychiatric Epidemiology 57:2, pages 411-422.
Crossref
Crossref
Hiroyoshi Takeuchi, Yasuhiro Mori & Yuichiro Tsutsumi. (2022) Pathophysiology, prognosis and treatment of tardive dyskinesia. Therapeutic Advances in Psychopharmacology 12, pages 204512532211173.
Crossref
Crossref
Ryan E Lawrence. (2022) Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts. Schizophrenia Bulletin Open 3:1.
Crossref
Crossref
Le Xiao, Qian Zhao, An-ning Li, Jushui Sun, Bin Wu, Lina Wang, Honggeng Zhang, Ruiling Zhang, Keqing Li, Xiaojin Xu, Tiebang Liu, Wenshun Zhang, Shiping Xie, Xiufeng Xu, Yunlong Tan, Kerang Zhang, Hongyan Zhang, Nianhong Guan, Mingji Xian, Motomichi Uki & Gang Wang. (2022) Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. Psychopharmacology 239:1, pages 243-251.
Crossref
Crossref
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
11
.
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
11
.
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1943
1952
.
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1859
1869
.
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1847
1857
.
Jelena Vrublevska & Lubova Renemane. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
823
853
.
Soumaya Touzani, Mohammed Hamdouni, Nawfal Houari, Youssef Yaakoubi Khbiza, Abderrahim Elbouazzaoui, Brahim Boukatta & Nabil Kanjaa. (2021) Neuroleptic malignant syndrome cases in a Moroccan intensive care unit: a retrospective analysis and literature review. Journal of Neurocritical Care 14:2, pages 88-97.
Crossref
Crossref
Lernik Hunanyan, Viktor Ghamaryan, Ani Makichyan & Elena Popugaeva. (2021) Computer-Based Drug Design of Positive Modulators of Store-Operated Calcium Channels to Prevent Synaptic Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences 22:24, pages 13618.
Crossref
Crossref
Marie Guitter, Vincent Laprevote, Adrian Lala, Livia Sturzu, Daniela Dobre & Raymund Schwan. (2020) Rate and predictors of interrupted patient follow‐up after first‐episode psychosis ‐ a retrospective cohort study in France. Early Intervention in Psychiatry 15:6, pages 1551-1563.
Crossref
Crossref
Emily Menand & Rachel Moster. (2021) Racial Disparities in the Treatment of Schizophrenia Spectrum Disorders: How Far Have We Come?. Current Behavioral Neuroscience Reports 8:4, pages 179-186.
Crossref
Crossref
Hideaki Tani, Masayuki Tomita, Takefumi Suzuki, Masaru Mimura & Hiroyuki Uchida. (2021) Clinical Characteristics of Patients with Schizophrenia Maintained without Antipsychotics: A Cross-sectional Survey of a Case Series. Clinical Psychopharmacology and Neuroscience 19:4, pages 773-779.
Crossref
Crossref
Masakazu Hatano, Ippei Takeuchi, Kanade Yamashita, Aoi Morita, Kaori Tozawa, Takashi Sakakibara, Genta Hajitsu, Manako Hanya, Shigeki Yamada, Nakao Iwata & Hiroyuki Kamei. (2021) Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan. Clinical Psychopharmacology and Neuroscience 19:4, pages 610-617.
Crossref
Crossref
Milica M Borovcanin & Katarina Vesic. (2021) Breast cancer in schizophrenia could be interleukin-33-mediated. World Journal of Psychiatry 11:11, pages 1065-1074.
Crossref
Crossref
Maria Fagerbakke Strømme, Liv Solrunn Mellesdal, Christoffer Bartz-Johannesen, Rune Andreas Kroken, Marianne Krogenes, Lars Mehlum & Erik Johnsen. (2021) Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study. Schizophrenia Research 235, pages 29-35.
Crossref
Crossref
. (2021) Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacology Reports 41:3, pages 266-324.
Crossref
Crossref
Tianmei Si, Ling Sun, Yilong Zhang & Lili Zhang. (2021) Dose Adjustment Model of Paliperidone in Patients With Acute Schizophrenia: A post hoc Analysis of an Open-Label, Single-Arm Multicenter Study. Frontiers in Psychiatry 12.
Crossref
Crossref
Sergey Yagoda, Christine Graham, Adam Simmons, Christina Arevalo, Ying Jiang & David McDonnell. (2020) Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectrums 26:4, pages 383-392.
Crossref
Crossref
Kai-Chun Yang, Yin-To Liao, Yen-Kuang Yang, Shih-Ku Lin, Chih-Sung Liang & Ya-Mei Bai. (2021) Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN). CNS Drugs 35:8, pages 893-905.
Crossref
Crossref
Lydia E Pieters, Jeroen Deenik, Diederik E Tenback, Jasper van Oort & Peter N van Harten. (2021) Exploring the Relationship Between Movement Disorders and Physical Activity in Patients With Schizophrenia: An Actigraphy Study. Schizophrenia Bulletin 47:4, pages 906-914.
Crossref
Crossref
Ruba Saleh Azfr Ali, Zahraa Jalal & Vibhu Paudyal. (2021) Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand?. General Psychiatry 34:4, pages e100561.
Crossref
Crossref
István Laszlovszky, Ágota Barabássy & György Németh. (2021) Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy 38:7, pages 3652-3673.
Crossref
Crossref
Jun Ishigooka, Ken Inada, Kazunari Niidome, Kazuo Aoki, Yoshitsugu Kojima, Shuichi Iwashita & Sakiko Yamada. (2021) Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study. Human Psychopharmacology: Clinical and Experimental 36:4.
Crossref
Crossref
Frank M. C. Besag, Michael J. Vasey & Iffah Salim. (2021) Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review. CNS Drugs 35:5, pages 507-526.
Crossref
Crossref
Deirdre Caffrey & Gillian L Sowden. (2020) A missed case of lurasidone induced laryngospasm: A case study and overview of extrapyramidal symptom identification and treatment. The International Journal of Psychiatry in Medicine 56:2, pages 73-82.
Crossref
Crossref
Qijing Bo, Xiaomeng Xing, Tian Li, Zhen Mao, Fuchun Zhou & Chuanyue Wang. (2021) Menstrual Dysfunction in Women With Schizophrenia During Risperidone Maintenance Treatment. Journal of Clinical Psychopharmacology 41:2, pages 135-139.
Crossref
Crossref
Hitoshi Sakurai, Norio Yasui-Furukori, Takefumi Suzuki, Hiroyuki Uchida, Hajime Baba, Koichiro Watanabe, Ken Inada, Yuka Sugawara Kikuchi, Toshiaki Kikuchi, Asuka Katsuki, Ikuko Kishida & Masaki Kato. (2021) Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry 54:02, pages 60-67.
Crossref
Crossref
Jose M. Rubio, Anil K. Malhotra & John M. Kane. (2021) Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia. Behavioural Brain Research 402, pages 113099.
Crossref
Crossref
Maximilian Huhn, Claudia Leucht, Philipp Rothe, Markus Dold, Stephan Heres, Susanne Bornschein, Thomas Schneider-Axmann, Alkomiet Hasan & Stefan Leucht. (2020) Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. European Archives of Psychiatry and Clinical Neuroscience 271:2, pages 293-302.
Crossref
Crossref
J. A. Arnaiz, C. Rodrigues-Silva, G. Mezquida, S. Amoretti, M. J. Cuesta, D. Fraguas, A. Lobo, A. González-Pinto, M. C. Díaz-Caneja, I. Corripio, E. Vieta, I. Baeza, A. Mané, C. García-Rizo, M. Bioque, J. Saiz, M. Bernardo & S. Mas. (2020) The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. Psychopharmacology 238:3, pages 665-676.
Crossref
Crossref
Hiroyuki Watanabe, Kazuyuki Nakamura, Ayumi Ishikawa, Jinwoo Lee, Yasunori Adachi, Toshitaka Nabeshima & Yoji Sugiura. (2021) A Case Report on Effect of Asenapine Sublingual Tablets on Intractable Nausea in a Patient of Terminal Malignant Lymphoma with Diabetes Who Cannot Take Oral Medicine糖尿病を合併した終末期悪性リンパ腫患者の経口投与が困難な難治性悪心に対してアセナピン舌下錠が著効した1例. Palliative Care Research 16:2, pages 133-138.
Crossref
Crossref
Antonio Inserra, Danilo De Gregorio & Gabriella Gobbi. (2020) Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews 73:1, pages 202-277.
Crossref
Crossref
Christian Fyhn Reuss, Jørgen Bo Hasselstrøm, Kristian Linnet, Dorte Jensen Christoffersen, Peter Mygind Leth, Lene Warner Thorup Boel & Jytte Banner. (2020) Increased risk of fatal intoxication and polypharmacy among psychiatric patients at death. Journal of Forensic Sciences 66:1, pages 255-264.
Crossref
Crossref
Lana Ganoci, Vladimir Trkulja, Maja Živković, Tamara Božina, Marina Šagud, Mila Lovrić & Nada Božina. (2021) ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 104, pages 110042.
Crossref
Crossref
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
10
.
Jason M Noel & Cherry W Jackson. (2020) ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. American Journal of Health-System Pharmacy 77:24, pages 2114-2132.
Crossref
Crossref
Stéphane Raffard, Nicolas Rainteau, Sophie Bayard, Yasmine Laraki, Joanna Norton & Delphine Capdevielle. (2020) Assessment of the efficacy of a fatigue management therapy in schizophrenia: study protocol for a randomized, controlled multi-centered study (ENERGY). Trials 21:1.
Crossref
Crossref
Christoph U. CorrellJohn W. NewcomerBernard SilvermanLauren DiPetrilloChristine GrahamYing JiangYangchun DuAdam SimmonsCraig HopkinsonDavid McDonnellRené S. Kahn. (2020) Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. American Journal of Psychiatry 177:12, pages 1168-1178.
Crossref
Crossref
Wolfgang Gaebel, Johannes Stricker & Mathias Riesbeck. (2020) The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples. Schizophrenia Research 225, pages 4-14.
Crossref
Crossref
Erik Johnsen, Rune A Kroken, Else-Marie Løberg, Maria Rettenbacher, Inge Joa, Tor Ketil Larsen, Solveig Klæbo Reitan, Berit Walla, Renata Alisauskiene, Liss Gøril Anda, Christoffer Bartz-Johannessen, Jan Øystein Berle, Jill Bjarke, Farivar Fathian, Kenneth Hugdahl, Eirik Kjelby, Igne Sinkeviciute, Silje Skrede, Lena Stabell, Vidar M Steen & W Wolfgang Fleischhacker. (2020) Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. The Lancet Psychiatry 7:11, pages 945-954.
Crossref
Crossref
Lasse Brandt, Tom Bschor, Jonathan Henssler, Martin Müller, Alkomiet Hasan, Andreas Heinz & Stefan Gutwinski. (2020) Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry 11.
Crossref
Crossref
Andrey Yu. Berezantsev, Georgiy P. Kostyuk, Larisa A. Burygina, Mikhail E. Levin & Anton V. Masyakin. (2020) The new stage in the development of a system for the treatment and rehabilitation of patients with schizophrenic spectrum disorders. Health Care of the Russian Federation 64:4, pages 181-189.
Crossref
Crossref
Michael J Crawford, Lavanya Thana, Rachel Evans, Alexandra Carne, Lesley O’Connell, Amy Claringbold, Arunan Saravanamuthu, Rebecca Case, Jasna Munjiza, Sandra Jayacodi, Joseph G Reilly, Elizabeth Hughes, Zoe Hoare, Barbara Barrett, Verity C Leeson, Carol Paton, Patrick Keown, Sofia Pappa, Charlotte Green & Thomas RE Barnes. (2020) Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT. Health Technology Assessment 24:44, pages 1-54.
Crossref
Crossref
Masakazu Hatano, Hiroyuki Kamei, Akane Shimato, Shigeki Yamada & Nakao Iwata. (2020) Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database. Psychiatry Research 291, pages 113249.
Crossref
Crossref
Aybeniz Civan Kahve, Hasan Kaya, Atike Gül Çakıl, Esra Ünverdi Bıçakçı, Pelin Göksel, Erol Göka & Ömer Böke. (2020) Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups?. Asian Journal of Psychiatry 52, pages 102063.
Crossref
Crossref
Minah Kim, Tak Hyung Lee, Wu Jeong Hwang, Tae Young Lee & Jun Soo Kwon. (2018) Auditory P300 as a Neurophysiological Correlate of Symptomatic Improvement by Transcranial Direct Current Stimulation in Patients With Schizophrenia: A Pilot Study. Clinical EEG and Neuroscience 51:4, pages 252-258.
Crossref
Crossref
Stephen J. Cooper & Gavin P. Reynolds. 2020. Seminars in Clinical Psychopharmacology. Seminars in Clinical Psychopharmacology
619
619
.
Sonia Shenoy, Amrtavarshini R, Rajeshkrishna P. Bhandary & Samir Kumar Praharaj. (2020) Frequency, reasons, and factors associated with antipsychotic polypharmacy in Schizophrenia: A retrospective chart review in a tertiary hospital in India. Asian Journal of Psychiatry 51, pages 102022.
Crossref
Crossref
Piyumi Fernando, Iris E.C. Sommer & Alkomiet Hasan. (2020) Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia?. Current Opinion in Psychiatry 33:3, pages 192-199.
Crossref
Crossref
Flavien Thuaire, Fabien Rondepierre, Elisabeth Bacon, Guillaume T. Vallet, Isabelle Jalenques & Marie Izaute. (2020) Executive functions in schizophrenia aging: Differential effects of age within specific executive functions. Cortex 125, pages 109-121.
Crossref
Crossref
Masato Usuki, Yuhei Kamiura, Ryo Okubo & Yoshio Yamanouchi. (2020)
Retracted
: National database study on the use of long‐acting antipsychotic injections and hospital readmission proportions in patients with schizophrenia in Japan
. Psychiatry and Clinical Neurosciences 74:3, pages 211-217.
Crossref
Crossref
M.V. Kurmyshev, M.S. Zaytseva, A.Yu. Kuzmenko & A.N. Khannanova. (2020) The use of long acting antipsychotics in outpatient care. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:6, pages 77.
Crossref
Crossref
Nadia Friend, Jade Hughes, Steve Kisely, Ratika Kumar & Dan Siskind. (2020) Appraisal of physical health guidelines for severe mental illness. Australian Health Review 44:6, pages 904.
Crossref
Crossref
Yutaro Shimomura, Yuhei Kikuchi, Takefumi Suzuki, Hiroyuki Uchida, Masaru Mimura & Hiroyoshi Takeuchi. (2020) Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Schizophrenia Research 215, pages 8-16.
Crossref
Crossref
Jelena Vrublevska & Lubova Renemane. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
31
.
Mario R. Louzã & Helio Elkis. 2020. Women's Mental Health. Women's Mental Health
49
58
.
S. Brissos. (2019) C.10.01 What do clinical goals mean to patients with schizophrenia?. European Neuropsychopharmacology 29, pages S595.
Crossref
Crossref
Afzal Javed, Holger Arthur, Logos Curtis, Lars Hansen & Sofia Pappa. (2019) Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and Therapy 8:2, pages 215-230.
Crossref
Crossref
Dongbin Lee, Ji Hyun Baek, Moonoh Bae, Yujin Choi & Kyung Sue Hong. (2019) Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes. Journal of Clinical Psychopharmacology 39:6, pages 591-596.
Crossref
Crossref
Jens Reimer, Jens Kuhn, Rita Wietfeld, Wolfgang Janetzky & Karolina Leopold. (2019) „Motivational interviewing“Motivational interviewing. Der Nervenarzt 90:11, pages 1144-1153.
Crossref
Crossref
Hervé Javelot, Francis Rangoni, Luisa Weiner & Bruno Michel. (2019) High-dose quetiapine and therapeutic monitoring. European Journal of Hospital Pharmacy 26:5, pages 285-287.
Crossref
Crossref
Jonathan G. Leung, Joseph Cusimano, Jessica M. Gannon, Olga Milgrom, Stephanie C. Valcourt, Joseph B. Stoklosa, Michael Kemp, William Olsufka, P. Brittany Vickery, Stephanie D. Nichols, Ericka L. Crouse, Chris Paxos, Emily K. Johnson & Brian A. Palmer. (2019) Addressing clozapine under-prescribing and barriers to initiation. International Clinical Psychopharmacology 34:5, pages 247-256.
Crossref
Crossref
Jiheon Kim, Ji-Hyeon Shin, Jeh-Kwang Ryu, Jae Hoon Jung, Chan-Hyung Kim, Hwa-Bock Lee, Do Hoon Kim, Sang-Kyu Lee & Daeyoung Roh. (2019) Physical performance is more strongly associated with cognition in schizophrenia than psychiatric symptoms. European Psychiatry 61, pages 72-78.
Crossref
Crossref
Peter Falkai, Alkomiet Hasan & Andrea Schmitt. 2019. 150 Years of Psychiatry at Göttingen University. 150 Years of Psychiatry at Göttingen University
85
96
.
Henry A. Nasrallah, Ralph Aquila, Yangchun Du, Arielle D. Stanford, Amy Claxton & Peter J. Weiden. (2018) Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectrums 24:4, pages 395-403.
Crossref
Crossref
Peter J. Weiden, Yangchun Du, Chih-Chin Liu & Arielle D. Stanford. (2018) Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS Spectrums 24:4, pages 419-425.
Crossref
Crossref
Jennifer Foresman, Ann Mitchell, Dianxu Ren & Heeyoung Lee. (2018) Implementing a brief healthy‐lifestyle group program on a psychiatric inpatient unit. Perspectives in Psychiatric Care 55:3, pages 424-429.
Crossref
Crossref
Kentaro Matsui, Takahiro Tokumasu, Yoshiteru Takekita, Ken Inada, Tetsufumi Kanazawa, Taishiro Kishimoto, Shotaro Takasu, Hideaki Tani, Seiichiro Tarutani, Naoki Hashimoto, Hiroki Yamada, Yoshio Yamanouchi & Hiroyoshi Takeuchi. (2019) Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. Schizophrenia Research 209, pages 50-57.
Crossref
Crossref
Ruth E. Cooper, Éanna Hanratty, Nicola Morant & Joanna Moncrieff. (2019) Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation. PLOS ONE 14:6, pages e0218711.
Crossref
Crossref
J Corey Fowler, Nathan Cope, Jonathan Knights, Peter Phiri, Andrew Makin, Tim Peters-Strickland & Shanaya Rathod. (2019) Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis. BMJ Open 9:6, pages e025952.
Crossref
Crossref
Jochen Gehrmann & Peter Götz Lampe. (2019) Serum Level Measurements Optimize Aripriprazole Treatment in Adolescent Patients. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 47:3, pages 261-264.
Crossref
Crossref
Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli & Antoine C. El Khoury. (2019) Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in Therapy 36:4, pages 858-869.
Crossref
Crossref
Monika Salgueiro & Rafael Segarra. (2019) Long-acting injectable second-generation antipsychotics in first-episode psychosis. International Clinical Psychopharmacology 34:2, pages 51-56.
Crossref
Crossref
Velprashanth Venkatesan, Sourav Khanra, Kamalika Mandal & MB Deepak. (2019) Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection. Clinical Neuropharmacology 42:2, pages 64-65.
Crossref
Crossref
Paola Bozzatello, Silvio Bellino, Irene Mancini, Luisa Sandei, Enrico Zanalda & Paola Rocca. (2018) Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. Clinical Drug Investigation 39:2, pages 169-178.
Crossref
Crossref
Theodora A. Manolis, Antonis A. Manolis & Antonis S. Manolis. (2018) Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. Angiology 70:2, pages 103-129.
Crossref
Crossref
Daniel Kamp, Christina Engelke, Thomas Wobrock, Wolfgang Wölwer, Georg Winterer, Christian Schmidt-Kraepelin, Wolfgang Gaebel, Berthold Langguth, Michael Landgrebe, Peter Eichhammer, Elmar Frank, Göran Hajak, Christian Ohmann, Pablo E. Verde, Marcella Rietschel, Ahmed Raees, William G. Honer, Berend Malchow, Thomas Schneider-Axmann, Peter Falkai, Alkomiet Hasan & Joachim Cordes. (2019) Left prefrontal high-frequency rTMS may improve movement disorder in schizophrenia patients with predominant negative symptoms – A secondary analysis of a sham-controlled, randomized multicenter trial. Schizophrenia Research 204, pages 445-447.
Crossref
Crossref
James E. Frampton. (2019) Brexpiprazole: A Review in Schizophrenia. Drugs 79:2, pages 189-200.
Crossref
Crossref
Peter Falkai, Alkomiet Hasan & Andrea Schmitt. 2019. 150 Jahre Universitätspsychiatrie in Göttingen. 150 Jahre Universitätspsychiatrie in Göttingen
83
96
.
I. N. Dyakov & S. K. Zyryanov. (2019) Clinical and economic efficiency of treatment with cariprazine in schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:7, pages 69.
Crossref
Crossref
Je-Yeon YunJung Suk LeeShi Hyun KangBeomwoo NamSeung Jae LeeSeung-Hwan LeeJoonho ChoiChan-Hyung KimYoung-Chul Chung. (2019) Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia. Korean Journal of Schizophrenia Research 22:2, pages 21.
Crossref
Crossref
Niruj Agrawal & Marco Mula. (2019) Treatment of psychoses in patients with epilepsy: an update. Therapeutic Advances in Psychopharmacology 9, pages 204512531986296.
Crossref
Crossref
Richard I.G. Holt. (2019) The Management of Obesity in People with Severe Mental Illness: An Unresolved Conundrum. Psychotherapy and Psychosomatics 88:6, pages 327-332.
Crossref
Crossref
M. Na Takuathung, N. Hanprasertpong, S. Teekachunhatean & N. Koonrungsesomboon. (2018)
Impact of
CYP1A2
genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta‐analysis
. Acta Psychiatrica Scandinavica 139:1, pages 15-25.
Crossref
Crossref
D. Mcintosh. (2019) C.13.01 Is functioning in patients with schizophrenia still under-prioritised?. European Neuropsychopharmacology 29, pages S627-S628.
Crossref
Crossref
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
H.-J. Assion, A. Schweppe, H. Reinbold & U. Frommberger. (2018) Pharmacological treatment for schizoaffective disorderPharmakologische Behandlung schizoaffektiver Störungen. Der Nervenarzt 90:S1, pages 1-8.
Crossref
Crossref
Wolfgang Gaebel, Alkomiet Hasan & Peter Falkai. 2019. S3-Leitlinie Schizophrenie. S3-Leitlinie Schizophrenie
51
137
.
Masakazu Hatano, Hiroyuki Kamei, Ippei Takeuchi, Kaori Tozawa, Shinya Makino, Manako Hanya, Shigeki Yamada & Nakao Iwata. (2018) The effects of different periods of co‐administration of oral and long‐acting injectable aripiprazole: A propensity score analysis. Human Psychopharmacology: Clinical and Experimental 34:1.
Crossref
Crossref
Christoph Potempa & Reinhard Rychlik. (2018) Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany. Health Economics Review 8:1.
Crossref
Crossref
Eric Achtyes, Adam Simmons, Anna Skabeev, Nikki Levy, Ying Jiang, Patricia Marcy & Peter J. Weiden. (2018) Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry 18:1.
Crossref
Crossref
Matthew J. Taylor & Seb Yim. (2018) Is there rebound psychosis on withdrawal of antipsychotic medication in schizophrenia?. Schizophrenia Research 201, pages 430-431.
Crossref
Crossref
Lei Sun, David McDonnell & Lisa von Moltke. (2018) Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia. Clinical Therapeutics 40:11, pages 1845-1854.e2.
Crossref
Crossref
Richard Newton, Alice Rouleau, Anna-Greta Nylander, Jean-Yves Loze, Henrike K. Resemann, Sara Steeves & Benedicto Crespo-Facorro. (2018) Diverse definitions of the early course of schizophrenia—a targeted literature review. npj Schizophrenia 4:1.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Advances in Therapy 35:10, pages 1612-1625.
Crossref
Crossref
Daisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, Krithika Rajagopalan & Antony Loebel. (2018) Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. Journal of Comparative Effectiveness Research 7:8, pages 737-748.
Crossref
Crossref
Diego Scheggia, Rosa Mastrogiacomo, Maddalena Mereu, Sara Sannino, Richard E. Straub, Marco Armando, Francesca Managò, Simone Guadagna, Fabrizio Piras, Fengyu Zhang, Joel E. Kleinman, Thomas M. Hyde, Sanne S. Kaalund, Maria Pontillo, Genny Orso, Carlo Caltagirone, Emiliana Borrelli, Maria A. De Luca, Stefano Vicari, Daniel R. Weinberger, Gianfranco Spalletta & Francesco Papaleo. (2018) Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nature Communications 9:1.
Crossref
Crossref
Jun Ishigooka, Shuichi Iwashita & Yoshihiro Tadori. (2018) Long‐term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52‐week, open‐label study. Psychiatry and Clinical Neurosciences 72:6, pages 445-453.
Crossref
Crossref
Baris Olten & Michael H. Bloch. (2018) Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 84, pages 272-281.
Crossref
Crossref
Andy Forbes, Mary Hobart, John Ouyang, Lily Shi, Stephanie Pfister & Mika Hakala. (2018) A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. International Journal of Neuropsychopharmacology 21:5, pages 433-441.
Crossref
Crossref
Paolo Girardi, Antonio Del Casale, Chiara Rapinesi, Georgios D. Kotzalidis, Francesca Splendori, Claudio Verzura, Giada Trovini, Serena Sorice, Dario Carrus, Iginia Mancinelli, Anna Comparelli, Sergio De Filippis, Antonio Francomano, Andrea Ballerini, Andrea Marcellusi, Francesco S. Mennini, Giuseppe Ducci, Gabriele Sani, Maurizio Pompili & Roberto Brugnoli. (2018) Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Human Psychopharmacology: Clinical and Experimental 33:3, pages e2658.
Crossref
Crossref
Shuhua Deng, Xiaojia Ni, Dewei Shang, Zhanzhang Wang, Ming Zhang, Jinqing Hu, Xiuqing Zhu, Haoyang Lu, Yuqing Chen, Yuefeng Zhang, Huan Peng & Yuguan Wen. (2018) Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. Journal of Clinical Psychopharmacology 38:2, pages 129-133.
Crossref
Crossref
Frédéric LimosinDrifa BelhadiDenis CometMaud PacouSophie BoujuKristel Van ImpePascal Guillon. (2018) Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients. Journal of Clinical Psychopharmacology 38:1, pages 19-26.
Crossref
Crossref
Leo Malandain, Florence Thibaut, Lamiae Grimaldi-Bensouda, Bruno Falissard, Lucien Abenhaim & Clementine Nordon. (2018) Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: Results from a nationwide cohort study. Schizophrenia Research 192, pages 213-218.
Crossref
Crossref
Dieter Naber, Ross A. Baker, Anna Eramo, Carlos Forray, Karina Hansen, Christophe Sapin, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Jean-Yves Loze & Steven G. Potkin. (2018) Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophrenia Research 192, pages 205-210.
Crossref
Crossref
Davide Amato, Anthony C. Vernon & Francesco Papaleo. (2018) Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. Neuroscience & Biobehavioral Reviews 85, pages 146-159.
Crossref
Crossref
Henk S Temmingh, Taryn Williams, Nandi Siegfried & Dan J Stein. (2018) Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database of Systematic Reviews 2018:2.
Crossref
Crossref
Nicolas Franck, Catherine Massoubre & Hélène Verdoux. 2018. Traité de Réhabilitation Psychosociale. Traité de Réhabilitation Psychosociale
273
284
.
Klára Látalová. (2017) The issue of tardive dyskinesia, focusing on the therapeutic potential of tetrabenazine. Psychiatrie pro praxi 18:3, pages 129-132.
Crossref
Crossref
Branimir Margetić, Branka Aukst Margetić, Dragutin Ivanec & Tija Žarković Palijan. (2017) What leads to high antipsychotic dosing in forensic patients with schizophrenia?. CNS Spectrums 22:6, pages 435-438.
Crossref
Crossref
Arnaud Tessier, Laurent Boyer, Mathilde Husky, Franck Baylé, Pierre-Michel Llorca & David Misdrahi. (2017) Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Research 257, pages 315-321.
Crossref
Crossref
O. Godin, M. Leboyer, F. Schürhoff, L. Boyer, M. Andrianarisoa, L. Brunel, E. Bulzacka, B. Aouizerate, F. Berna, D. Capdevielle, T. D'Amato, H. Denizot, C. Dubertret, J. Dubreucq, C. Faget, F. Gabayet, P.M. Llorca, J. Mallet, D. Misdrahi, C. Passerieux, R. Rey, R. Richieri, A. Schandrin, M. Urbach, P. Vidailhet, D. Costagliola, G. Fond, M. Andrianarisoa, B. Aouizerate, F. Berna, O. Blanc, L. Brunel, E. Bulzacka, D. Capdevielle, I. Chereau-Boudet, G. Chesnoy-Servanin, J.M. Danion, T. D'Amato, A. Deloge, C. Delorme, H. Denizot, J.M. Dorey, C. Dubertret, J. Dubreucq, C. Faget, C. Fluttaz, G. Fond, S. Fonteneau, F. Gabayet, E. Giraud-Baro, M.C. Hardy-Bayle, D. Lacelle, C. Lançon, H. Laouamri, M. Leboyer, T. Le Gloahec, Y. Le Strat, P.M. Llorca, J. Mallet, E. Metairie, D. Misdrahi, I. Offerlin-Meyer, C. Passerieux, P. Peri, S. Pires, C. Portalier, R. Rey, C. Roman, M. Sebilleau, A. Schandrin, F. Schürhoff, A. Tessier, A.M. Tronche, M. Urbach, F. Vaillant, A. Vehier, P. Vidailhet, J. Vilain, E. Vilà, H. Yazbek & A. Zinetti-Bertschy. (2017) Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. Journal of Psychiatric Research 94, pages 62-69.
Crossref
Crossref
Jasmin Grigg, Roisin Worsley, Caroline Thew, Caroline Gurvich, Natalie Thomas & Jayashri Kulkarni. (2017) Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology 234:22, pages 3279-3297.
Crossref
Crossref
Ana Isabel Wu Chou, Yu-Chiao Wang, Cheng-Li Lin & Chia-Hung Kao. (2017) Female schizophrenia patients and risk of breast cancer: A population-based cohort study. Schizophrenia Research 188, pages 165-171.
Crossref
Crossref
Alex Hofer, Verena Radner, Monika Edlinger, Georg Kemmler, Maria A. Rettenbacher & W. Wolfgang Fleischhacker. (2017) Why do indiviuals with schizophrenia drop out of observational clinical trials?. Psychiatry Research 256, pages 1-5.
Crossref
Crossref
Francesca Managò & Francesco Papaleo. (2017) Schizophrenia: What’s Arc Got to Do with It?. Frontiers in Behavioral Neuroscience 11.
Crossref
Crossref
Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Alessandro Serretti & Robin Emsley. (2017) Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International Clinical Psychopharmacology 32:5, pages 235-248.
Crossref
Crossref
D. R. Gotfredsen, R. S. Wils, C. Hjorthøj, S. F. Austin, N. Albert, R. G. Secher, A. A. E. Thorup, O. Mors & M. Nordentoft. (2017) Stability and development of psychotic symptoms and the use of antipsychotic medication – long-term follow-up. Psychological Medicine 47:12, pages 2118-2129.
Crossref
Crossref
Displaying 200 of 303 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list